コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 he middle and distal parts, and three at the gastroesophageal junction).
2 arcinoma of the stomach and 29 patients with gastroesophageal junction.
3 ocally advanced adenocarcinoma of stomach or gastroesophageal junction.
4 me anatomic site (1.0-2.0 cm superior to the gastroesophageal junction.
5 metastatic adenocarcinoma of the stomach and gastroesophageal junction.
6 correlated with the (18)F-FDG uptake at the gastroesophageal junction.
7 asia seen in some cases, particularly at the gastroesophageal junction.
8 system delivers radiofrequency energy to the gastroesophageal junction.
9 ination after radiofrequency ablation at the gastroesophageal junction.
10 d marker and target of transformation at the gastroesophageal junction.
11 t from passive mechanical distraction of the gastroesophageal junction.
12 d genomic dosage in an adenocarcinoma of the gastroesophageal junction.
13 resectable adenocarcinoma of the stomach or gastroesophageal junction.
14 ad primary tumors in the distal esophagus or gastroesophageal junction.
15 endoscopic biopsies above, at, and below the gastroesophageal junction; 2) esophageal motility; and 3
16 nts to radiofrequency energy delivery to the gastroesophageal junction (35 patients) or to a sham pro
17 ent in mismatch repair deficient/MSI gastric/gastroesophageal junction adenocarcinoma and the first a
18 patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma to evaluate act
19 ction of stage IB through IV (M0) gastric or gastroesophageal junction adenocarcinoma were randomly a
20 gnosis in patients with distal esophageal or gastroesophageal junction adenocarcinoma who have receiv
21 Patients with histologic proof of gastric or gastroesophageal junction adenocarcinoma with a Karnofsk
22 rpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Tri
24 ion After a curative resection of gastric or gastroesophageal junction adenocarcinoma, postoperative
25 rs with stage IB through IV (M0) gastric and gastroesophageal junction adenocarcinoma, previously ran
29 radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Demonstrated s
30 veness in reducing mortality from esophageal/gastroesophageal junction adenocarcinomas has not been e
31 ed by gastroesophageal reflux disease in the gastroesophageal junction and associated with tumorigene
33 the type and condition of the mucosa at the gastroesophageal junction and its relation to gastroesop
35 velopment of metaplasia and neoplasia at the gastroesophageal junction and suggests practical guideli
36 The RCs for recognizing the location of the gastroesophageal junction and the diaphragmatic hiatus w
37 ed with HER2 PET and CT (12% esophageal, 64% gastroesophageal junction, and 24% gastric adenocarcinom
38 py of local and locally advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas,
39 ry site (distal one-third, middle one-third, gastroesophageal junction, and proximal one-third), Laur
41 plasia in an endoscopically normal-appearing gastroesophageal junction are histologic indicators of g
42 lumnar junction and 3) 5-10 mm distal to the gastroesophageal junction, as demarcated by the top of t
43 ined as eradication of IM (in esophageal and gastroesophageal junction biopsy specimens), documented
44 ence in adenocarcinomas of the esophagus and gastroesophageal junction by relatively low resolution g
47 slelizumab in patients with advanced gastric/gastroesophageal junction cancer and elevated tumor DKK1
48 ments for patients with advanced gastric and gastroesophageal junction cancer have not been widely ex
50 s with midesophageal to distal esophageal or gastroesophageal junction cancer planned for curative re
51 Therapy of patients with advanced gastric or gastroesophageal junction cancer should provide symptom
52 T) imaging in seven patients with gastric or gastroesophageal junction cancer showed high probe uptak
53 , and patients with HER2-positive gastric or gastroesophageal junction cancer were given the maximum
54 reviously untreated metastatic esophageal or gastroesophageal junction cancer were randomly assigned
55 an associated infection in one patient with gastroesophageal junction cancer who received 3 mg/kg on
56 1%; 6.1-45.6) of 19 patients with gastric or gastroesophageal junction cancer who received evorpacept
58 cal stage II or III EC, excluding those with gastroesophageal junction cancer, who underwent trimodal
62 otherapy for locally advanced esophageal and gastroesophageal junction cancers is based on a few posi
63 emoradiation and resection of esophageal and gastroesophageal junction cancers on the basis of the ph
64 results with a large series of patients with gastroesophageal junction cancers, TTE can be performed
66 to assume that intestinal metaplasia at the gastroesophageal junction develops as a result of chroni
67 ress this, we harvested tissues spanning the gastroesophageal junction from healthy and diseased dono
68 T1 adenocarcinoma of the distal esophagus or gastroesophageal junction from January 1985 to December
69 first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma; howeve
70 th locally advanced resectable (LAR) gastric/gastroesophageal junction (G/GEJ) adenocarcinomas have a
71 all-cell lung cancer (NSCLC), and gastric or gastroesophageal junction (G/GEJ) cancer who received pe
73 as demonstrated clinical activity in gastric/gastroesophageal junction (G/GEJ) patients with elevated
74 chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma and is as
75 aclitaxel as second-line therapy for gastric/gastroesophageal junction (GEJ) adenocarcinoma with prog
80 iate esophageal versus gastric epithelium in gastroesophageal junction (GEJ) biopsies, the histology
81 (47.2%) had gastric cancer, 111 (21.6%) had gastroesophageal junction (GEJ) cancer, and 161 (31.3%)
85 erapy for resectable gastric cancer (GC) and gastroesophageal junction (GEJ) tumors, including the ef
88 g to primary tumor location into two groups: gastroesophageal junction (GEJ)/cardia and distal gastri
89 were more frequent in proximal (esophageal, gastroesophageal junction [GEJ], and cardia) tumors than
93 patients with carcinoma of the esophagus or gastroesophageal junction has been surgery, although pri
94 ith adenocarcinoma of the gastric cardia and gastroesophageal junction have no history of reflux.
95 pathogenesis of intestinal metaplasia at the gastroesophageal junction have yielded contradictory res
97 the lower frequency of tumors arising at the gastroesophageal junction in comparison with distal gast
98 carcinomas arising in the stomach or in the gastroesophageal junction in patients with HER2-positive
100 o III cancer of the mid-/distal-esophagus or gastroesophageal junction, measurable disease, and Easte
104 s epithelium and 3 biopsy specimens from the gastroesophageal junction of 3 patients without Barrett'
105 axation nadir also typically occurred before gastroesophageal junction opening (median, 2.1 seconds;
106 hincter relaxation onset invariably preceded gastroesophageal junction opening (median, 5.0 seconds;
107 ent lower esophageal sphincter relaxation to gastroesophageal junction opening in an unsedated human
108 ly untreated advanced HER2-negative gastric, gastroesophageal junction or esophageal adenocarcinoma.
109 Transformation associated with reflux at the gastroesophageal junction reflects activation by bile ac
110 lthough progression to adenocarcinoma at the gastroesophageal junction reflects exposure to acid and
112 of intestinal metaplasia located only at the gastroesophageal junction than it has been in patients w
113 rough studies showed a pocket of acid at the gastroesophageal junction that escaped the buffering eff
114 tients with resectable adenocarcinoma of the gastroesophageal junction treated with or without neoadj
115 thoracic esophageal carcinoma, including the gastroesophageal junction tumors (Siewert I), were rando
117 cancer localized in the distal esophagus or gastroesophageal junction undergoing McKeown TMIE or Ivo
118 ch, carina, and one vertebral body above the gastroesophageal junction was 13.9, 14.3, and 15.1 mm, r
119 xtent of the endoscopic BE segment above the gastroesophageal junction were 0.95 and 0.94, respective
120 resectable adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to rece
121 th resected adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to surg
123 currence of adenocarcinoma of the stomach or gastroesophageal junction who have undergone curative re